Q-omics provides the consensus-scored EIF4BP8 profile across patient tissues and cancer cell-line models. EIF4BP8 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EIF4BP8 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, EIF4BP8 RNA expression shows 8,575 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, HNSC, and LAML as cancer lineages where EIF4BP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4BP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4BP8 survival associations across molecular data types. EIF4BP8 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4BP8 RNA expression–survival associations across cancer types. High EIF4BP8 expression shows unfavorable associations in LIHC, OV and BRCA, but favorable associations in KIRC, READ and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for EIF4BP8 RNA expression.
This table summarizes EIF4BP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for EIF4BP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4BP8 shows lower tumor expression in BRCA and higher tumor expression in HNSC, COAD, LUSC, LUAD and PRAD. The HNSC box plot shows higher EIF4BP8 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p < 0.001).
This table shows molecular features associated with EIF4BP8 in patient tissues and cancer cell lines. In patient samples, EIF4BP8 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
